Humam Shahare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Humam Shahare has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Chaudhry
Crescent Theranostics, Anaheim, CA 982902, USA
1 shared publication - Ammar Chaudhry
AstraZeneca, Gaithersburg, MD 20878, USA
1 shared publication - Charles A. James
Department of Radiology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas (S.J., D.B., J.S., R.R., C.J.).
1 shared publication - Dhruba Dasgupta
Department of Radiology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas (S.J., D.B., J.S., R.R., C.J.).
1 shared publication - Huma Muzaffar
Crescent Theranostics, Anaheim, CA 982902, USA
1 shared publication - Jasmeet Singh
Department of Radiology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas (S.J., D.B., J.S., R.R., C.J.).
1 shared publication
Latest Publications
- 8 June 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (9) , 3597-3603
Radiology Challenging Case Competition: A Mentoring/Education Opportunity for Medical Students
- 8 June 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (9) , 3597-3603
Radiology Challenging Case Competition: A Mentoring/Education Opportunity for Medical Students
- Open Access
From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer
Prostate cancer, a leading cause of cancer-related mortality among men, is characterized by complex genetic and epigenetic alterations, dysregulation of oncogenic pathways, and a dynamic tumor microenvironment. Advances in molecular diagnostics and targeted therapies have significantly transformed the management of this disease. Prostate-specific membrane antigen (PSMA) has emerged as a critical biomarker, enhancing the precision of prostate cancer diagnosis and treatment. Theranostics, which integrates PSMA-targeted imaging with radioligand therapies, has shown remarkable efficacy in detecting and treating advanced prostate cancer. By leveraging the dual capabilities of PSMA-based diagnostics and therapeutic agents, theranostics offers a personalized approach that improves patient outcomes. This comprehensive review explores the latest developments in PSMA-targeted theranostics and their impact on the future of prostate cancer management, highlighting key clinical trials and emerging therapeutic strategies.
Open AccessFrom Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer
Prostate cancer, a leading cause of cancer-related mortality among men, is characterized by complex genetic and epigenetic alterations, dysregulation of oncogenic pathways, and a dynamic tumor microenvironment. Advances in molecular diagnostics and targeted therapies have significantly transformed the management of this disease. Prostate-specific membrane antigen (PSMA) has emerged as a critical biomarker, enhancing the precision of prostate cancer diagnosis and treatment. Theranostics, which integrates PSMA-targeted imaging with radioligand therapies, has shown remarkable efficacy in detecting and treating advanced prostate cancer. By leveraging the dual capabilities of PSMA-based diagnostics and therapeutic agents, theranostics offers a personalized approach that improves patient outcomes. This comprehensive review explores the latest developments in PSMA-targeted theranostics and their impact on the future of prostate cancer management, highlighting key clinical trials and emerging therapeutic strategies.